Atossa Therapeutics (ATOS)
NASDAQ:ATOS
Want to see ATOS full AI Analyst Report?
Top Page
Atossa Therapeutics
(NASDAQ:ATOS)
Select Model
Select Model
Rating:48Neutral
Price Target:
$5.00
▼(-14.24% Downside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and accelerating cash burn with shrinking equity). Technicals are neutral with modest near-term support but a weaker longer-term trend. Corporate events provide some offset via improved listing/IP overhangs, while valuation is constrained by continued unprofitability and no dividend support.
Positive Factors
Debt-free Balance Sheet
A debt-free capital structure materially lowers fixed obligations and interest risk for a clinical-stage biotech that lacks product cash flows. Over the next 2-6 months this preserves financing optionality and reduces near-term insolvency pressure, allowing management to prioritize development milestones over debt servicing.
Negative Factors
No Revenue and Widening Losses
Persistent zero revenue combined with materially widening net losses is a core structural weakness for a clinical-stage firm. Without product cash flows, the company remains entirely dependent on external financing to fund operations and trials, increasing dilution and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free Balance Sheet
A debt-free capital structure materially lowers fixed obligations and interest risk for a clinical-stage biotech that lacks product cash flows. Over the next 2-6 months this preserves financing optionality and reduces near-term insolvency pressure, allowing management to prioritize development milestones over debt servicing.
Read all positive factors
Atossa Therapeutics (ATOS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$42.63M
Dividend YieldN/A
Average Volume (3M)1.16M
Price to Earnings (P/E)―
Beta (1Y)1.97
Revenue GrowthN/A
EPS Growth-40.23%
CountryUS
Employees15
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.37
Shares Outstanding8,611,361
10 Day Avg. Volume1,949,046
30 Day Avg. Volume1,157,820
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.94
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-916.22
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
$23.00Price Target Upside294.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-4.48
Revenue Forecast (FY)N/A
Atossa Therapeutics Business Overview & Revenue Model
Company Description
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug cand...
How the Company Makes Money
null...
Atossa Therapeutics Earnings Call Summary
Earnings Call Date:Mar 25, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Aug 17, 2026
Earnings Call Sentiment Positive
The earnings call presented a generally positive outlook with notable reductions in operating costs and promising clinical advancements for (Z)-endoxifen, particularly in metastatic breast cancer. However, the financial impact of a write-off and decreased interest income offset some of these positives.Positive Updates
Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
Negative Updates
Investment Write-off
A write-off of $1.7 million was recorded as Dynamic Cell Therapies ceased operations in the fourth quarter of 2024.
Read all updates
Q4-2024 Updates
Positive
Negative
Reduced Operating Expenses
Total operating expenses for the year were $27.6 million, down from $31.4 million in 2023, a decrease of $3.8 million, reflecting disciplined spending in both R&D and G&A.
Read all positive updates
Company Guidance
In their recent earnings call, Atossa Therapeutics provided guidance highlighting several key metrics. Operating expenses for 2024 decreased to $27.6 million, down from $31.4 million in 2023, due to disciplined spending in R&D and G&A. R&D expenses fell by $3.2 million to $14.1 million, driven by a $2.6 million reduction in spending on (Z)-endoxifen trials. G&A expenses decreased slightly to $13.5 million, with a $1.9 million reduction in compensation costs. The company reported a net loss of $25.5 million or $0.20 per share, compared to $30.1 million or $0.24 per share in the previous year. Atossa closed the year with $71.1 million in cash and cash equivalents, providing a strong financial position to advance their lead program, (Z)-endoxifen, particularly in metastatic breast cancer settings. Additionally, a Phase I study demonstrated a clinical benefit rate of approximately 26% in patients with previous progression on multiple therapies, and a related Phase II study suggested nearly a five-month improvement in progression-free survival for certain subgroups. The company plans to focus on the U.S. FDA process for a streamlined path to market, with further guidance expected as they engage with key opinion leaders and regulatory authorities.Atossa Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.00K | -16.00K | -17.00K | -23.00K | -8.00K | -23.00K |
| EBITDA | -39.02M | -37.13M | -27.60M | -31.35M | -27.68M | -20.50M |
| Net Income | -37.64M | -34.77M | -25.50M | -30.09M | -26.96M | -20.61M |
Balance Sheet | ||||||
| Total Assets | 37.94M | 47.61M | 76.44M | 96.25M | 123.53M | 141.26M |
| Cash, Cash Equivalents and Short-Term Investments | 31.72M | 41.30M | 71.08M | 88.46M | 110.89M | 136.38M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.46M | 8.26M | 4.97M | 5.24M | 5.57M | 3.13M |
| Stockholders Equity | 30.49M | 39.35M | 71.48M | 91.02M | 117.96M | 138.14M |
Cash Flow | ||||||
| Free Cash Flow | -33.40M | -29.79M | -21.05M | -20.95M | -20.79M | -16.48M |
| Operating Cash Flow | -33.38M | -29.76M | -21.03M | -20.94M | -20.76M | -16.47M |
| Investing Cash Flow | -14.00K | -23.00K | -19.00K | -14.00K | -4.73M | -9.00K |
| Financing Cash Flow | 0.00 | 0.00 | 3.67M | -1.48M | 0.00 | 113.30M |
Atossa Therapeutics Technical Analysis
Negative
5.83
Price Trends
5.30
Negative
5.94
Negative
9.18
Negative
Market Momentum
-0.14
Positive
47.60
Neutral
57.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATOS, the sentiment is Negative. The current price of 5.83 is above the 20-day moving average (MA) of 5.23, above the 50-day MA of 5.30, and below the 200-day MA of 9.18, indicating a bearish trend. The MACD of -0.14 indicates Positive momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 57.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ATOS.
Atossa Therapeutics Risk Analysis
Atossa Therapeutics disclosed 49 risk factors in its most recent earnings report. Atossa Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atossa Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $457.27M | -2.41 | -22.51% | ― | 1199.64% | 30.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $42.63M | -1.18 | -84.91% | ― | ― | -40.23% | |
48 Neutral | $138.25M | 0.81 | -23.05% | ― | 24.46% | ― | |
47 Neutral | $103.66M | -15.27 | -666.47% | ― | -100.00% | 46.40% | |
46 Neutral | $102.82M | -1.40 | -26.58% | ― | -1.44% | 11.50% | |
44 Neutral | $36.01M | -0.72 | 315.97% | ― | ― | 38.95% |
* Healthcare Sector Average
ATOS
Atossa Therapeutics
5.12
-7.08
-58.03%
AGEN
Agenus
3.41
0.39
12.91%
INO
Inovio Pharmaceuticals
1.25
-0.75
-37.50%
OVID
Ovid Therapeutics
2.54
2.25
775.86%
SEER
Seer
1.89
-0.10
-5.03%
TVGN
Tevogen Bio Holdings
7.19
-58.31
-89.02%
Atossa Therapeutics Corporate Events
Executive/Board ChangesShareholder MeetingsStock Split
Atossa Therapeutics Shareholders Approve Proposals at 2026 Meeting
Positive
May 8, 2026
On May 7, 2026, Atossa Therapeutics held its 2026 Annual Meeting of Stockholders, with 8,611,361 common shares eligible to vote as of the March 19, 2026 record date. Stockholders elected three Class II directors, ratified Ernst Young LLP as indep...
Business Operations and StrategyLegal Proceedings
Atossa Therapeutics Resolves Endoxifen Patent Disputes, Clarifies Rights
Positive
Apr 16, 2026
On April 16, 2026, Atossa Therapeutics reported that it had entered into a Settlement Agreement on April 13, 2026, with Intas Pharmaceuticals and Jina Pharmaceuticals to resolve patent disputes over Endoxifen-related intellectual property, includi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.